Skip to main content
. 2023 Feb 28;149(10):6989–6998. doi: 10.1007/s00432-023-04601-9

Table 2.

Hematologic adverse events of study participants according to CTCAE V5

FLOT
(n = 20 patients)
FLO/mFOLFOX
(n = 3 patients)
FOLFIRINOX
(n = 5 patients)
Grade 1/2/3/4 1/2/3/4 1/2/3/4
Hematological 0/4/8/8 2/1/0/0 0/0/4/1
Anemia 10/4/1/0 1/1/0/0 3/0/2/0
Thrombocytopenia 7/0/0/0 1/1/0/0 1/0/1/0
Leukocytopenia 0/10/5/1 2/1/0/0 0/3/1/0
Neutropenia 1/2/7/8 1/0/0/0 0/0/3/1